Latanoprost, the next step in antiglaucoma therapy | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

1620528

Reference Type

Journal Article

Title

Latanoprost, the next step in antiglaucoma therapy

Author(s)

Goldenberg, MM

Year

1996

Is Peer Reviewed?

Journal

P & T
ISSN: 1052-1372

Report Number

IPA/97/1126344

Volume

VOL 21 ISS Oct 1996

Issue

REF 15

Page Numbers

526-528

Language

eng

Abstract

IPA COPYRIGHT: ASHP The chemistry, mechanism of action, pharmacokinetics, results of clinical studies, and pharmacy and therapeutics committee implications of latanoprost (13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2alpha-isopropyl ester; PhXA-41; Xalatan) for glaucoma therapy are briefly described.

Keywords

Latanoprost; glaucoma; overview; Mechanism of action; Pharmacokinetics; Clinical studies; Pharmacy and therapeutics committee; considerations; Prostaglandin derivatives; 13; PhXA-41; Xalatan